Drugs / OTSA101-DTPA-90Y
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04176016 | Jan 2020 → Jan 2024 | synovial sarcoma | OncoTherapy Science, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01469975 | Dec 2011 → Feb 2015 | synovial sarcoma | Centre Leon Berard | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTSA101-DTPA-90Y | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01469975 ↗ |
| Known as | OTSA-101 | “BACKGROUND: Synovial Sarcomas (SS) are rare tumors occurring predominantly in adolescent and young adults with a dismal prognosis in advanced phases. We report a first-in-human...” PMID 29884132 ↗ Jun 2018 |
| Modality | Monoclonal antibody | “OncoTherapy Science Inc. has developed a chimeric humanized monoclonal antibody (mAb) against FZD10, named OTSA101.” NCT01469975 ↗ |
| Route | Intravenous | “OTSA101-DTPA-90Y will be administered IV as a single injection” NCT01469975 ↗ |
| Target | FZD10 | “a chimeric humanized monoclonal antibody (mAb) against FZD10” NCT01469975 ↗ |